MPT Resource Center

A product to protect women against HIV and pregnancy is a no-brainer. Why isn’t there one?

Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy

Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy

Two into one does go: Formulation development of a multipurpose combination vaginal ring releasing dapivirine and metronidazole for prevention of HIV infection and treatment of bacterial vaginosis

Common ground: the opportunity of male contraceptives as MPTs

Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy

Preferences for Long-Acting PrEP Products Among Women and Girls: A Quantitative Survey and Discrete Choice Experiment in Eswatini, Kenya, and South Africa

Preferences, educational messaging, and demand creation channels for multipurpose-prevention technologies (MPTs) among women in South Africa

pH-triggered polymeric nanoparticles in gel for preventing vaginal transmission of HIV and unintended pregnancy

Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy

Program impact and potential pitfalls of multi-purpose technologies (MPTs) for HIV prevention and contraception

Attitudes Toward Menstrual Suppression Among Cyclic and Continuous Contraceptive Vaginal Ring Users in Kenya

End-to-end approach to ensuring equitable access to multipurpose prevention technologies in low- and middle-income countries

Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptability

Safety of multiple administrations of spermicidal LL-37 antimicrobial peptide into the mouse female reproductive tract

Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya

Commentary: Multipurpose prevention technologies—What about sexually transmitted infections?

Synthesis of end-user research to inform future multipurpose prevention technologies in sub-Saharan Africa: a scoping review

Optimizing the pipeline of multipurpose prevention technologies: opportunities across women’s reproductive lifespans

A Brief History and Advancement of Contraceptive Multipurpose Prevention Technology (cMPT) Products

Equipping providers to offer novel MPTs: Developing counseling messages for the Dual Prevention Pill in clinical studies and beyond

Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis

Prospective acceptability of a multipurpose technology (MPT) implant in preclinical development to prevent HIV and unplanned pregnancy: Qualitative insights from women end users and health care providers in South Africa and Zimbabwe

Polyphenylene carboxymethylene (PPCM), the active component of the topical contraceptive Yaso-GEL, exhibits potent antimicrobial activity against Neisseria gonorrhoeae in preclinical studies

Microarray patch for HIV prevention and as a multipurpose prevention technology to prevent HIV and unplanned pregnancy: an assessment of potential acceptability, usability, and programmatic fit in Kenya

Preferred product attributes of a multipurpose vaginal ring: Findings from a phase 1 trial

Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development

Expanding the pipeline for multipurpose prevention technologies: compounds with potential activity to prevent or treat HIV and other STIs

A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm

Acceptability of an intravaginal ring for simultaneously preventing HIV infection and pregnancy: Qualitative findings of the Kisumu Combined Ring Study, 2019

Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045)

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.

Reservoir-Style Polymeric Drug Delivery Systems: Empirical and Predictive Models for Implant Design

Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic

17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, is an effective spermicide and microbicide against Neisseria gonorrhoeae

Development of Immunocontraceptives in Female

Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037)

Poster abstract: Multipurpose vaginal rings for HIV prevention and non-hormonal contraception

Couples’ decision making regarding the use of multipurpose prevention technology (MPT) for pregnancy and HIV prevention

Couples’ Preferences for “2 in 1” Multipurpose Prevention Technologies to Prevent Both HIV and Pregnancy: Results of a Discrete Choice Experiment in Uganda and Zimbabwe

Preferences for Multipurpose Technology and Non-oral Methods of Antiretroviral Therapy Among Women Living With HIV in Western Kenya: A Survey Study

Female and male partner perspectives on placebo Multipurpose Prevention Technologies (MPTs) used by women in the TRIO study in South Africa and Kenya

Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications

Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel

Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones

Current Status of Multipurpose Prevention Technology (MPT) Development

Current Status of Multipurpose Prevention Technology (MPT) Development 2015 click to view Journal Article In this Journal Article: Health Risk(s): HIV STI / STD Unintended Pregnancy Product Type(s): MPTs Topic(s): Product Development Product Trials Region(s): Global

Ethical issues for late-stage trials of multipurpose prevention technologies for HIV and pregnancy

Ethical issues for late-stage trials of multipurpose prevention technologies for HIV and pregnancy November 2014 click to view Journal Article In this Journal Article: Health Risk(s): HIV Unintended Pregnancy Product Type(s): MPTs Topic(s): MPTs

Multipurpose prevention technologies for reproductive and sexual health

Multipurpose prevention technologies for reproductive and sexual health November 2014 click to view Journal Article In this Journal Article: Health Risk(s): HIV STI / STD Unintended Pregnancy Product Type(s): MPTs Topic(s): Product Development Product Trials Region(s): Global

Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures

Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures 17 June 2014 click to view Journal Article In this Journal Article: Product Type(s): Nanofibers Topic(s): Product Development

Multipurpose Prevention Technologies: Maximising Positive Synergies – Jan 2014

Multipurpose Prevention Technologies: Maximising Positive Synergies – Jan 2014 January 2014 click to view Journal Article In this Journal Article: Health Risk(s): HIV STI / STD Unintended Pregnancy Product Type(s): MPTs Topic(s): Product Development Region(s): Global